GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Manhattan-based dentist Dr. Sandip Sachar and obesity medicine specialist Dr. Meghan Garcia-Webb discuss the prevalence of ...

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, ...

Patients with diabetes mellitus who use GLP-1 RAs have an increased risk for acute and chronic pancreatitis, according to a study presented at DDW 2025.

The revolutionary GLP-1 class of weight loss drugs are racking up blockbuster sales at a pace rarely seen in the pharmaceutical industry. But the pharma industry’s gain is the food industry’s ...

“Beyond diabetes and obesity, research is now underway to explore the potential of GLP-1 agonists for other conditions like kidney disease, heart failure, Alzheimer’s, Parkinson’s, sleep apn ...

Study Rundown: GLP-1 receptor agonists have shown neuroprotective effects in laboratory models of Parkinson’s disease. However, it remains unclear whether these medications can modify the course of ...

This study found that using GLP-1 RAs and SGLT2is for type 2 diabetes treatment offers potential neuroprotections against Alzheimer disease and related dementias. HealthDay News — Both glucagon ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them. (HealthDay News) — Both glucagon-like peptide-1 receptor agonists ...